India’s NHRC Calls for Mandatory Anti‑Venom Stocking – Lessons for Pakistan

India’s NHRC Directive on Anti‑Snake‑Venom: What It Means for South Asia

Snakebite remains a hidden public‑health emergency across South Asia. In India, the National Human Rights Commission (NHRC) has recently pulled up multiple states and Union Territories for failing to maintain adequate anti‑snake‑venom (ASV) supplies, after several preventable deaths were reported in district hospitals. The move has reignited debate on supply‑chain resilience, regulatory oversight, and community awareness – issues that resonate far beyond India’s borders.

The NHRC’s Intervention – A Brief Overview

• Mandate: The NHRC directed every state and UT to ensure that ASV is readily available in all snake‑bite‑prone districts, especially at primary health centres, community health centres and district hospitals.
• Trigger: A series of fatal snakebite cases in Odisha, Uttar Pradesh and other states highlighted chronic stock‑outs. The commission’s report cited multiple deaths directly linked to the unavailability of polyvalent anti‑venom.
• Legal Backing: The directive follows a Public Interest Litigation (PIL) before the Supreme Court, which underscored India’s staggering ≈58,000 snakebite deaths per year – the highest globally – and called for systemic reforms.
• Geographic Focus: The NHRC noted that 70 % of these deaths occur in low‑altitude areas of nine states – Bihar, Jharkhand, Madhya Pradesh, Odisha, Uttar Pradesh, Andhra Pradesh, Telangana, Rajasthan and Gujarat.

These actions signal a shift from treating snakebite as a peripheral issue to recognising it as a human‑rights concern.

Why the Shortage Persists – Root Causes

These inter‑linked challenges mean that even when ASV is technically available at the national level, it rarely reaches the patients who need it most.

Impact on Snakebite Treatment in South Asia

1. Increased Mortality – Delayed administration of ASV is the single most lethal factor. The WHO recommends a 30‑minute window from bite to first dose; stock‑outs push this window well beyond safe limits.
2. Higher Morbidity – Survivors often suffer long‑term complications (e.g., renal failure, tissue necrosis) when treatment is delayed, increasing the burden on families and health systems.
3. Economic Losses – Rural households lose primary earners, and the cost of treating complications can push families into poverty.
4. Erosion of Trust – Repeated failures to provide life‑saving drugs undermine confidence in public health services, encouraging reliance on unverified traditional remedies.

While the data above primarily reflect the Indian scenario, neighbouring countries such as Pakistan, Bangladesh and Nepal share similar epidemiological patterns – high snakebite incidence in agricultural regions, limited health‑facility coverage, and reliance on a narrow set of ASV manufacturers.

Pakistan’s Current ASV Landscape

• The National Institute of Health (NIH), Islamabad, produces a polyvalent equine‑derived ASV covering four of Pakistan’s most venomous snakes: Naja naja (cobra), Bungarus caeruleus (krait), and two others (details in the NIH technical sheet). The product is licensed and distributed to government hospitals.
• Despite domestic production, reports of stock‑outs in peripheral districts surface periodically, especially during the monsoon season when snake encounters rise.
• Pakistan’s health‑system decentralisation places procurement responsibilities on provincial health departments, leading to uneven supply‑chain performance across provinces.

These realities suggest that Pakistan is not immune to the same vulnerabilities that prompted India’s NHRC intervention.

Policy Recommendations for Pakistan

1. Institutionalise a National ASV Buffer Stock

• Target: Maintain a three‑month national reserve covering at least 90 % of projected annual snakebite cases.
• Mechanism: Centralised procurement by the federal Ministry of Health, with periodic audits by an independent committee.

2. Strengthen Domestic Manufacturing Capacity

• Upgrade NIH facilities to increase batch size and diversify antivenom formulations (e.g., inclusion of Echis carinatus venom).
• Encourage private‑sector participation through incentives, quality‑assurance frameworks, and technology transfer agreements.

3. Deploy Real‑Time Inventory Management

• Implement a digital logistics platform linking district hospitals, provincial stores and the central depot.
• Use mobile‑based reporting for frontline health workers to flag low stock levels instantly.

4. Align Funding with Epidemiology

• Allocate state‑specific budgets based on snakebite incidence data (e.g., higher allocations for Punjab’s rural belts, Khyber Pakhtunkhwa’s hilly zones).
• Leverage international donor programs focused on neglected tropical diseases to supplement domestic funding.

5. Community Awareness and First‑Aid Training

• Launch a national snakebite awareness campaign (radio, TV, social media) emphasizing rapid hospital transport and the dangers of delayed treatment.
• Train village health workers in basic first‑aid (immobilisation, pressure‑band application) and in recognizing signs that require immediate ASV.

6. Regulatory Streamlining for Imports

• Create an expedited approval pathway for WHO‑prequalified ASV products from reputable manufacturers, ensuring a backup supply when domestic production lags.

Monitoring and Accountability

A robust monitoring framework can prevent the recurrence of shortages:

• Quarterly public dashboards showing ASV stock levels per district.
• Independent audits by the NHRC‑style body in Pakistan (e.g., the Human Rights Commission of Pakistan) to hold provincial authorities accountable.
• Performance‑linked incentives for provinces that achieve 100 % ASV availability in designated health facilities.

Potential Risks and Mitigation Strategies

A Regional Outlook

India’s NHRC directive could serve as a regional catalyst. If neighboring countries adopt similar rights‑based approaches, South Asia may develop a coordinated anti‑venom network, sharing surplus stocks during emergencies and harmonising quality standards. Such collaboration would align with the WHO’s “Snakebite Envenoming: A Neglected Tropical Disease” strategy, which calls for cross‑border cooperation.

Conclusion

The NHRC’s firm stance on anti‑snake‑venom availability highlights a critical gap in South‑Asian health systems: life‑saving medicines are often treated as peripheral commodities rather than essential public goods. Pakistan, while already producing its own polyvalent ASV, must institutionalise supply‑chain resilience, expand manufacturing, and strengthen community outreach to avoid the tragic outcomes now evident in parts of India. By learning from the NHRC’s experience and implementing the policy steps outlined above, Pakistan can safeguard its rural populations and set a benchmark for regional snakebite management.

For further reading, see the NHRC press releases on anti‑venom shortages and the NIH’s technical dossier on polyvalent ASV.